The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Pitt B, Steg G, Leiter LA, Bhatt DL. Cardiovasc Drugs Ther. 2021 Nov 09; doi: 10.1007/s10557-021-07291-y. Epub 2021 Nov 09. PMID: 34750713
The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Pitt B, Steg G, Leiter LA, Bhatt DL. Cardiovasc Drugs Ther. 2021 Nov 09; doi: 10.1007/s10557-021-07291-y. Epub 2021 Nov 09. PMID: 34750713
The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Pitt B, Steg G, Leiter LA, Bhatt DL. Cardiovasc Drugs Ther. 2021 Nov 09; doi: 10.1007/s10557-021-07291-y. Epub 2021 Nov 09. PMID: 34750713